NEXI Stock Overview
A clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
NexImmune, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.11 |
| 52 Week High | US$28.69 |
| 52 Week Low | US$0.10 |
| Beta | 1.94 |
| 1 Month Change | -50.91% |
| 3 Month Change | -49.73% |
| 1 Year Change | -98.51% |
| 3 Year Change | -99.89% |
| 5 Year Change | n/a |
| Change since IPO | -99.98% |
Recent News & Updates
Recent updates
NexImmune (NASDAQ:NEXI) Will Have To Spend Its Cash Wisely
Sep 07
Neximmune GAAP EPS of -$0.69 misses by $0.01
Aug 15NexImmune gains aftermarket on IND clearance for NEXI-003 to treat HPV-related cancers
Jul 14NexImmune: Selling For Under Cash Value
May 31Here's Why We're A Bit Worried About NexImmune's (NASDAQ:NEXI) Cash Burn Situation
May 26We're Keeping An Eye On NexImmune's (NASDAQ:NEXI) Cash Burn Rate
Dec 19Shareholder Returns
| NEXI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -27.1% | 0.2% | -0.2% |
| 1Y | -98.5% | -4.7% | 25.8% |
Return vs Industry: NEXI underperformed the US Biotechs industry which returned -4.7% over the past year.
Return vs Market: NEXI underperformed the US Market which returned 25.8% over the past year.
Price Volatility
| NEXI volatility | |
|---|---|
| NEXI Average Weekly Movement | 46.8% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NEXI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NEXI's weekly volatility has increased from 34% to 47% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 6 | Craig Jalbert | www.neximmune.com |
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company’s product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials.
NexImmune, Inc. Fundamentals Summary
| NEXI fundamental statistics | |
|---|---|
| Market cap | US$139.61k |
| Earnings (TTM) | -US$20.62m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs NEXI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NEXI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$20.62m |
| Earnings | -US$20.62m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -14.78 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NEXI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/06 22:44 |
| End of Day Share Price | 2025/01/06 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
NexImmune, Inc. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Kaveri Pohlman | BTIG |
| Alethia Young | Cantor Fitzgerald & Co. |